Akkermansia muciniphila composition

A composition and drug technology, applied in the field of Akkermansia composition, can solve the problems of high risk of blood sugar excursion and superposition of side effects

Inactive Publication Date: 2020-05-29
SHANGHAI INST FOR ENDOCRINE & METABOLIC DISEASES +1
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The technical problem to be solved by the present invention is to overcome the technical problem of superposition of side effects and high risk of hypoglycemia events and blood sugar excursi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Akkermansia muciniphila composition
  • Akkermansia muciniphila composition
  • Akkermansia muciniphila composition

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0046] Wherein, the preparation method of the Akkermansia freeze-dried powder preferably comprises the following steps:

[0047] The centrifuged cells of Akkermansia are evenly mixed with freeze-drying protective agent and water, and then freeze-dried.

[0048] Wherein, the centrifuged cells of Akkermansia are preferably obtained according to the following method: centrifuge the fermentation liquid of Akkermansia and collect the cells. The centrifugation is a conventional operation in the field, for example, centrifugation at 8000 rpm for 20 minutes.

[0049] Wherein, based on the mass of the pharmaceutical composition, the viable count of Akkermansia in the Akkermansia freeze-dried powder is preferably 10 6 -10 14 CFU / g, more preferably 10 10 CFU / g.

[0050] Wherein, the raw material of the lyoprotectant is a conventional lyoprotectant raw material in the art. For example, in a preferred embodiment of the present application, the lyoprotectant is a mixture of sodium glut...

Embodiment 1

[0081] Embodiment 1: Akkermansia metformin compound tablet preparation

[0082] (1) Preparation of W03 freeze-dried powder

[0083] ① Freeze-drying protective agent: sodium glutamate, mannitol, trehalose, milk powder.

[0084] ② After the fermentation of W03 bacteria, the fermentation liquid was centrifuged at 8000rpm for 20min to collect the bacteria.

[0085] ③ Akkermansia centrifugation obtained thalline is mixed with freeze-drying protective agent and water, so that the mass percentages of sodium glutamate, mannitol, trehalose, and milk powder in the solution before freeze-drying are respectively 2%, 2%, 4% and 8%, freeze-dried to obtain freeze-dried bacterial powder, the number of live bacteria of the Akkermansia strain whose preservation number is CGMCC No.14764 in the bacterial powder is 10 10 CFU / g. The obtained W03 bacteria powder is pulverized and stored in a turnover barrel sealed for future use.

[0086] (2) Preparation of Metformin Granules

[0087] 10kg of m...

Embodiment 2

[0091] Example 2: Preparation of Akkermansia metformin compound enteric-coated capsules

[0092] (1) Preparation of W03 freeze-dried powder

[0093] ① Freeze-drying protective agent: sodium glutamate, mannitol, trehalose, milk powder.

[0094] ②After the fermentation of W03 bacteria, the fermentation liquid was centrifuged at 8000rpm for 20min, and the bacteria were collected.

[0095] ③ Akkermansia centrifugation obtained thalline is mixed with freeze-drying protective agent and water, so that the mass percentages of sodium glutamate, mannitol, trehalose, and milk powder in the solution before freeze-drying are respectively 2%, 2%, 4% and 8%, freeze-dried to obtain freeze-dried bacterial powder, the number of live bacteria of the Akkermansia strain whose preservation number is CGMCC No.14764 in the bacterial powder is 10 10 CFU / g. The obtained W03 bacteria powder is pulverized and stored in a turnover barrel sealed for future use.

[0096] (2) Preparation of Metformin Gra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of akkermansia muciniphila compositions, and provides a medicine composition. The medicine composition comprises Akkermansia muciniphila and metformin, wherein on the basis of the mass of the medicine composition, the number of the live akkermansia muciniphila is 10<6>-10<14> CFU/g, and the content of the metformin is 20-60%.

Description

technical field [0001] The present invention relates to an Akkermansia composition, more particularly to an Akkermansia composition for preventing and treating metabolic diseases. Background technique [0002] Obesity is a worldwide health problem. According to the Global Burden of Disease study, the global obesity epidemiology is gradually deteriorating, which has a negative impact on physical health and health economics. Internationally, the body mass index (BMI) is usually used as the standard to judge the degree of obesity. When 18.5≤BMI≤24.9 is in the normal range, BMI≥25 is considered overweight, and BMI≥30 is considered obese. Research data from 195 countries around the world shows that since 1980, the incidence of obesity has doubled. At present, 5% of children and 12% of adults are obese. 1 / 5 of the world's population will be obese. From 1975 to 2014, the global average BMI of men increased from 21.7 to 24.2kg / m 2 , women increased from 22.1 to 24.4kg / m 2 . As ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/74A61P3/00A61P3/04A61P3/10A61P5/50A61K31/155
CPCA61K35/74A61K31/155A61P3/00A61P3/04A61P3/10A61P5/50
Inventor 宁光文彬王卫庆于鸿晶洪洁马新顾卫琼高远王计秋孙宁云刘瑞欣徐晓芬
Owner SHANGHAI INST FOR ENDOCRINE & METABOLIC DISEASES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap